Replies to post #241793 on Biotech Values

[DewDiligence]

NVAX's selloff today may stem from the unwillingness of Congress (so far) to commit more funding for COVID vaccines and therapeutics. (This was a pretty big topic on MRNA's webcast yesterday.)

[vinmantoo]

I don't follow VIR - ouch
Playing the covid game as an investment is high risk high reward
the good news for the ENTAs of the world is that covid is very much still around.

I bought a very small amount of VIR as it was the only MAb that worked against Omicron. When I bought it it was about 3x smaller than my smallest position and it is now even smaller by 35% from my initial in all. I don't like losing money but it wasn't so much.

Agree about ENTA. Congress needs to appropriate more money for Covid because this damn virus isn't going away any time soon. That would help both ENTA and NVAX